Idiopathic Pulmonary Fibrosis Treatment Market Size Worth USD 8.3 Billion in 2032 | Emergen Research

The global Idiopathic Pulmonary Fibrosis (IDF) treatment market size was USD 3.51 Billion in 2022 and is expected to register a rapid revenue CAGR of 6.2% during the forecast period. The global Idiopathic Pulmonary Fibrosis (IPF) treatment market is experiencing significant growth driven by increasing research and development (R&D) activities and rapid technological advancements, according to a recent market research report.

Key factors propelling market revenue growth include the development of novel antifibrotic and immunomodulatory therapies targeting specific molecular pathways involved in IPF progression. Drugs such as Pirfenidone and Nintedanib, belonging to different classes like MAPK inhibitor, tyrosine kinase, and autotaxin, have shown promising results in slowing or even reversing disease progression.

Request a Sample Report with Table of Contents and Figures to click Here: @ https://www.emergenresearch.com/request-sample/2800

The rising prevalence of IPF, with an estimated 100,000 people affected in the U.S. alone and 30,000 to 40,000 new cases diagnosed each year, further drives market growth. Environmental exposures, including asbestos and silica dust, are associated with an increased risk of IPF.

Investments in R&D are on the rise as pharmaceutical companies recognize the untapped potential of the IPF treatment market. Patient advocacy groups are also playing a significant role in raising awareness and encouraging R&D efforts.

Technological advancements are revolutionizing IPF treatment approaches. Cell-based therapies and collaborations such as the partnership between Brainomix and Bridge Biotherapeutics to develop AI-powered imaging analysis for BBT-877, a novel autotaxin inhibitor, exemplify the integration of technology in advancing IPF treatment strategies.

Market Restraints

The high cost of treatment remains a significant restraint on market revenue growth. Developing new drugs involves extensive research, clinical trials, and regulatory approvals, leading to high drug prices that may limit accessibility, particularly in reimbursement policies.

Requesting A Customised Report @https://www.emergenresearch.com/request-for-customization/2800

In terms of market segmentation, MAPK inhibitors dominate the IPF treatment market, offering targeted approaches to treatment with potentially fewer side effects compared to traditional NSAIDs or corticosteroids. TKIs are also gaining traction, showing improvements in lung function and survival outcomes in clinical trials.

Among drug types, Pirfenidone holds a significantly large market share, being the first drug approved for IPF treatment. Its relatively favorable side effect profile and widespread adoption among healthcare professionals and patients contribute to its dominance. Nintedanib, while experiencing moderate growth, offers a distinct treatment approach and has demonstrated comparable efficacy in clinical trials.

Hospitals emerge as the dominant end-use segment due to their advanced diagnostic facilities, infrastructure, and resources essential for accurately diagnosing and managing IPF. Additionally, hospitals provide centralized care, easy access to medical services, and respiratory therapies crucial for IPF management.

Overall, the global IPF treatment market is witnessing robust growth driven by advancements in R&D, increasing prevalence, technological innovations, and the introduction of novel therapies. However, challenges such as high treatment costs persist, underscoring the need for continued investment in research and development to address unmet medical needs and improve patient outcomes.

To Read More About The Report, Visit @https://www.emergenresearch.com/industry-report/idiopathic-pulmonary-fibrosis-treatment-market

IDF Treatment Top Companies and Competitive Landscape

The global IPF treatment market is fairly fragmented, with many large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing a more effective Idiopathic Pulmonary Fibrosis (IDF) treatment market.

• AstraZeneca
• Biogen
• Boehringer Ingelheim International GmbH
• Hoffmann-La Roche Ltd.
• FibroGen, Inc.
• Mission Therapeutics
• GNI Group Ltd.
• Bristol Myers Squibb Company
• Cipla Inc.
• Amgen Inc.

IDF Treatment Latest Industry News

• On 24 October 2023, Bristol Myers Squibb announced the approval of Therapy Designation from U.S. FDA for Investigational LPA1 Antagonist in treating progressive pulmonary fibrosis. LPA1 activation play a crucial role in the development of pulmonary fibrosis. Preclinical in vitro and in vivo studies have shown that LPA1 antagonism may offer promising therapeutic benefits for treating lung injury and fibrosis. This designation expedites development and regulatory review process, potentially bringing this innovative treatment to patients faster.

• On 9 August 2023, Pliant Therapeutics announced commencement of BEACON-IPF, a Phase 2b clinical trial assessing the efficacy and safety of bexotegrast, an oral, small molecule inhibitor of integrins αvβ6 and αvβ1, in the treatment of IPF. This trial builds upon encouraging results from the Phase 2a INTEGRIS-IPF trial, which demonstrated bexotegrast's potential efficacy and safety in IPF patients. This initiation of BEACON-IPF represents a significant advancement in the development of bexotegrast as a potential treatment for IPF, a progressive and life-threatening lung disease with limited treatment options.

IDF Treatment Market Segment Analysis

For the purpose of this report, Emergen Research has segmented the global Idiopathic Pulmonary Fibrosis (IDF) treatment market on the basis of drug class, drug type, end-use, and region:

• Drug Class Outlook (Revenue, USD Billion; 2019-2032)
o MAPK inhibitor
1. Esbriet
o Tyrosine Kinase
1. Ofev
o Autotaxin Inhibitors
1. GLPG 1690

• Drug Type Outlook (Revenue, USD Billion; 2019-2032)
o Pirfenidone
o Nintedanib

• End-Use Outlook (Revenue, USD Billion; 2019-2032)
o Hospital
o Clinics
o Pharmacies

• Regional Outlook (Revenue, USD Billion; 2019-2032)
o North America
1. U.S.
2. Canada
3. Mexico
o Europe
1. Germany
2. France
3. UK
4. Italy
5. Spain
6. Benelux
7. Rest of Europe
o Asia Pacific
1. China
2. India
3. Japan
4. South Korea
5. Rest of APAC
o Latin America
1. Brazil
2. Rest of LATAM
o Middle East & Africa
1. Saudi Arabia
2. UAE
3. South Africa
4. Turkey
5. Rest of Middle East & Africa

To Purchase Now, Click Here @https://www.emergenresearch.com/select-license/2800

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

This release was published on openPR.